An observational study in Aging and Muscle Loss, sponsored by McMaster University. Recruiting at 1 site in Canada. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-08.
Sponsored by McMaster University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Muscular Atrophy with a site in Canada — 1 open to participants now, 2 under way, 1 of them phase 3. Muscular Atrophy · Canada.
Among the 29 studies in Muscular Atrophy with a site in Canada, this one is one of 5 that started in 2023, is one of 2 observational ones, and was the 28th registered.
413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.
Browse Muscular Atrophy studies →1 of the 29 studies in Muscular Atrophy with a site in Canada is open now.
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 61 across 73 observational studies indexed under Muscular Atrophy.
Median enrollment 26 across the 27 interventional studies, 206 across the 2 observational. Of the 26 that completed or were terminated, 4 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 29 have an industry lead sponsor. The 10 most frequent:
McMaster University is the lead sponsor of 742 studies on the registry; 127 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
McMaster University has 9 studies filed under Muscular Atrophy — fewer than ten, so there is no comparison to draw.
1 of the studies in Muscular Atrophy with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06630949McMaster UniversityD3-Creatine and Skeletal Muscle in Older Adults | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Muscular Atrophy with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The age-related decline in muscle mass and strength are collectively referred to as sarcopenia. However, the tools currently employed to assess skeletal muscle mass (SMM) (e.g., Dual-energy Xray Absorptiometry; DXA) have substantial drawbacks, and it is known that DXA-lean soft tissue (LST) is generally not associated with health outcomes of interest. Thus, the investigators propose using a novel, non-invasive, stable isotope-labelled probe (Deuterium (D)-labelled creatine (D3-creatine; D3-Cr)) to measure skeletal muscle mass in a large cohort of older individuals. The development and employment of new methods to accurately quantify the biological substrate of sarcopenia, skeletal muscle, are critical for the measure to remain clinically relevant. The plan is to measure 350 persons from the recently established (M3) prospective cohort. There will be measurement of lean soft tissue LST and appendicular LST (aLST) using DXA and compared to D3-Cr-measured SMM (D3-Cr-SMM) at baseline, 12mo, and 24mo (2yr) of follow-up. Physical mobility will also be measured (using various instruments).
The tools currently employed to assess skeletal muscle mass (SMM), including DXA, have substantial drawbacks. DXA does not measure muscle per se but provides an assessment of lean soft tissue (LST) as a proxy for skeletal muscle. Even if confined to the appendages (aLST), DXA assessments include many non-muscle constituents (e.g., connective tissue, water), which are poorly and inconsistently related to mobility and falls with aging. As a superior measure to DXA, the investigators will use a novel, stable isotope-labelled probe to measure SMM. This method uses the oral ingestion of a small dose of deuterium (D)-labelled creatine (D3-creatine; D3-Cr), which is irreversibly converted to creatinine when taken up by skeletal muscle. The dilution of the labelled creatinine provides a safe, non-invasive, and highly accurate measure of SMM. The utilization of D3-Cr-measured SMM (D3-Cr-SMM) requires no specific diet and requires only the collection of a spot urine sample.
The plan is to recruit a sub-sample of older Canadians between 60 and 80 living in the greater Hamilton-Toronto area. Participants will be recruited through the MacM3 (M3) cohort study. MacM3 will enroll a sample of 2,000 participants from a pre-recruited representative sample of more than 10,000 older adults living in the greater Hamilton and Toronto areas who consented to be contacted for further research as part of a larger research platform. From this pool of 2000 individuals in MacM3, the plan is to recruit 350 people. Participants will be classified across the three levels of mobility limitations based on the MacM3 screening criteria of preclinical mobility limitation (i.e., able to manage without difficulty - no mobility limitation, able to manage without difficulty but sometimes with task modification - early mobility limitation, and able to manage with minor difficulty - minor mobility limitation, which will provide valuable insight into whether changes in D3-Cr-SMM are associated with a change in categorical mobility status.
The proposed research design is a prospective cohort study including 350 older (65-80 y) men and women. All participants will undergo muscle mass assessments via D3-Cr, body composition (LST, aLST, fat mass) via DXA, and dietary intake by 24h recall (ASA24) at baseline, 1y and 2y of follow-up. Performance-based assessments of physical function, mobility status and muscular strength will also be conducted at baseline, 1y and 2y of follow-up. During the quarterly follow-up phone calls, all participants will be screened limitation screening questions (see inclusion criteria), allowing us to capture changes in mobility status (i.e., no, early, minor or major mobility limitation) over time.
The cohort will be a sub-sample from the McMaster Monitoring My Mobility (MacM3) cohort, a newly founded research cohort. The MacM3 cohort is a longitudinal study of community-dwelling older Canadians (age 60-80 y at baseline) with different levels of mobility limitation (i.e., able to manage without difficulty - no mobility limitation; able to manage without difficulty but with task modification - early mobility limitation; and able to manage with minor difficulty - minor mobility limitation) collecting detailed mobility and health data on participants over two years of follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants will be considered eligible for this study if they are
Participants must fall into one of three self-reported mobility limitations based on validated screening criteria via a structured phone interview. Potential participants will be asked whether they have any difficulty:
Response options include:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Muscle mass
D3-creatine-measured muscle mass
Time frame: 2 years
Lean tissue mass
DXA-measured lean tissue mass
Time frame: 2 years
Questionnaire Mobility
Questionnaire-based assessment of participant's physical mobility
Time frame: 2 years
SPPB
Short physical performance battery (SPPB)
Time frame: 2 years
Timed up and go
Participant starts in a seated position, stands up upon go signal, walks 3 meters, turns around, walks back to the chair and sits down. The time stops when the patient is seated
Time frame: 2 years
Plan to share: Undecided — We will evaluate all requests to obtain IPD when the study is complete.
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.
Of 36 non-industry observational studies under Muscular Atrophy, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 66. This study's planned 38 months is above that.
Counting every sponsor, half of 38 studies reached it within 35 months; a quarter within 18 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.